«YTD, IMV shares have generated strong returns of 125 %, with 37 % of this generated since our Top Pick update, and we see strong price
appreciation potential on forthcoming DPX - Survivac clinical updates as described above, independent of any new pipeline advances that Immunovaccine may undertake
during our
forecast period.